arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Emergent BioSolutions Inc.

EBS
$6.64 ▼ -0.11 (-1.63%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
18 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
65
Health
Fair
Bearish
auto_awesome

Analytical Summary

Emergent BioSolutions Inc. faces fundamental challenges with weakness in Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $355.2M
Dividend Yield —
Revenue Growth -28.8% ↘
Op. Margin 13.5% ↗
ROIC 5.7% ↗
FCF / Share $2.93 ↗
Trailing P/E 6.8x
Price / Book 0.7x
FCF Yield 44.1%
Debt / Equity 1.13
info Valuation on last close. End-of-day price, Sep 23, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$742.90M
↓ -28.8% —
Net Income Profit after all expenses
$52.60M
↑ +127.6% —
Operating Margin Operating profit as % of sales
13.5%
↑ +229.4% 64th
FCF / Share Free cash flow per share
$2.93
↑ +333.9% —
Long-Term Debt Long-term obligations
$589.70M
↓ -15.8% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Profitability ↓
68
Returns ↓
68
Financial Health →
43
Cash Quality ↑
91

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 18 years · 68 quarters